Jeff Jamison, PhD
Chief Development Officer
Dr. Jamison has worked in ophthalmic research and drug discovery for over 25 years and has a degrees in Electrical (B.S.) and Biomedical (Ph.D.) Engineering. As a PhD candidate in Dr. Paul Sieving’s lab at the University of Michigan, he worked to isolate and model components of the electroretinogram (ERG) using agents to block retinal cell function, transgenic animal models, and studying patients with retinal disease. Dr. Sieving’s passion for patient advocacy inspired Dr. Jamison to pursue a career in the pharmaceutical industry.
At Pfizer Global Research and Alcon Laboratories his research focused on the development of novel animal models and high throughput methods to screen drug candidates in disease areas such as Diabetes, Glaucoma and Age Related Macular Degeneration.
In 2009, Dr. Jamison established Ophthy-DS Inc., a preclinical contract research organization (CRO) which specialized in evaluation of ocular toxicology, development of in vivo assays and models of ocular disease and recently he joined Experimentica US in a similar role as the Director of In Vivo Pharmacology.
Dr. Jamison has helped countless customers from multinational pharmaceutical companies to small bio-techs further their ocular drug discovery programs.